151 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author최호순-
dc.date.accessioned2018-03-29T01:55:55Z-
dc.date.available2018-03-29T01:55:55Z-
dc.date.issued2014-12-
dc.identifier.citationEUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 26(12), p.1353-1359en_US
dc.identifier.issn0954-691X-
dc.identifier.issn1473-5687-
dc.identifier.urihttps://journals.lww.com/eurojgh/Abstract/2014/12000/Short_term_probiotic_therapy_alleviates_small.8.aspx-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/53568-
dc.description.abstractAim: Although numerous animal studies suggest that probiotic therapy has beneficial effects in various liver diseases, the evidence for beneficial effects in human liver disease is controversial. This study was carried out to investigate the efficacy of probiotic therapy in alleviating small intestinal bacterial overgrowth (SIBO) and permeability in chronic liver disease. Methods: Fifty-three patients with chronic liver disease were randomized to either probiotic therapy or placebo. Six bacterial species were used: Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophilus. After 4 weeks, changes in the composition of fecal bacteria, SIBO, intestinal permeability, and clinical symptoms were examined. Results: Three of the six probiotic species, B. lactis, L. rhamnosus, and L. acidophilus, increased in the feces of the probiotic therapy group (P<0.001), whereas there was no change in fecal microbiota in the placebo group. SIBO disappeared in many individuals of the probiotic therapy group, but none in the placebo (24 vs. 0%, P<0.05). General gastrointestinal symptoms also improved more in the probiotic group and improvement in intestinal permeability was slightly but not significantly more frequent in the probiotic arm than the placebo arm (50 vs. 31.3%, P=0.248). Numbers of lactobacilli in stool were correlated negatively with intestinal permeability (P for trend<0.05). Liver chemistry did not improve significantly in either group. Conclusions: We conclude that short-term probiotic administration in chronic liver disease is effective in alleviating SIBO and clinical symptoms, but ineffective in improving intestinal permeability and liver function. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.en_US
dc.description.sponsorshipThis study was supported by a grant from the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A121185).en_US
dc.language.isoenen_US
dc.publisherLIPPINCOTT WILLIAMS & WILKINSen_US
dc.subjectchronic liver diseaseen_US
dc.subjectintestinal permeabilityen_US
dc.subjectprobioticen_US
dc.subjectsmall intestinal bacterial overgrowthen_US
dc.titleShort-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver diseaseen_US
dc.typeArticleen_US
dc.relation.no12-
dc.relation.volume26-
dc.identifier.doi10.1097/MEG.0000000000000214-
dc.relation.page1353-1359-
dc.relation.journalEUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY-
dc.contributor.googleauthorKwak, Dong Shin-
dc.contributor.googleauthorJun, Dae Won-
dc.contributor.googleauthorSeo, Jae Gu-
dc.contributor.googleauthorChung, Won Seok-
dc.contributor.googleauthorPark, Soon-Eung-
dc.contributor.googleauthorLee, Kang Nyeong-
dc.contributor.googleauthorKhalid-Saeed, Waqar-
dc.contributor.googleauthorLee, Hang Lak-
dc.contributor.googleauthorLee, Oh Young-
dc.contributor.googleauthorChoi, Ho Soon-
dc.relation.code2014029235-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidhschoi96-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE